
The Dexus (ASX: DXS) share price is in focus as the company announced it has priced a $500 million subordinated notes issue to bolster financial flexibility and diversify funding sources.
What did Dexus report?
- A$500 million in new subordinated notes issued across two 30-year tranches
- First tranche: A$250 million floating rate notes, non-call period of 5.25 years, margin of 1.75% over 3-month BBSW
- Second tranche: A$250 million fixed rate notes, non-call period of 8.25 years, initial coupon of 6.30%, swapped back to floating, 1.85% margin
- Implied yield of 5.48%, with settlement expected on 10 December 2025
- Notes receive 50% equity credit from Standard & Poor’s and Moody’s
What else do investors need to know?
This capital management initiative comes as Dexus looks to strengthen its balance sheet and pursue investment opportunities in a disciplined way. By issuing these subordinated notes, Dexus aims to further diversify its funding sources and lengthen its debt maturity profile to help support ongoing business strategy.
The notes do not contain equity conversion features, and their issuance follows strong demand from both new and existing investors. The proceeds are intended to support investment activity while maintaining prudent capital management and ongoing capital recycling.
What’s next for Dexus?
Dexus intends to use the proceeds from the new subordinated notes to enhance its financial flexibility going forward. Management notes that investment decisions will be made with a continued focus on preserving balance sheet strength while pursuing growth opportunities across its portfolio.
With settlement of the notes expected on 10 December 2025, Dexus will continue executing on its strategy to unlock value for investors, maintain a diversified funding base and build long-term resilience for its listed and funds management businesses.
Dexus share price snapshot
Over the past 12 months, Dexus shares have risen 1%, slightly trailing the S&P/ASX 200 Index (ASX: XJO) which has increased 2% over the same period.
The post Dexus issues $500 million in new subordinated notes to boost flexibility appeared first on The Motley Fool Australia.
Should you invest $1,000 in Dexus right now?
Before you buy Dexus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Dexus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 18 November 2025
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- How on earth has the WiseTech Global share price exploded 20% in 17 days?
- ASX healthcare stock debuts at a massive discount to its initial public offer price
- Fletcher Building updates funding: repays USPP, extends bank facilities
- 5 things to watch on the ASX 200 on Friday
- AMP suspends AMPPB hybrid notes for redemption and removal
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.
Leave a Reply